Galmed Pharmaceuticals Ltd. GLMD Financial Statement Data


2025 Q2

Submissions

Field Row 1
adsh 0001641172-25-002362
cik 1595353
name GALMED PHARMACEUTICALS LTD.
sic 2834
countryba IL
stprba
cityba RAMAT GAN
zipba 5250608
bas1 C/O MEITAR LAW OFFICES
bas2 16 ABBA HILLEL SILVER RD.
baph 97236938448
countryma IL
stprma
cityma RAMAT GAN
zipma 5250608
mas1 C/O MEITAR LAW OFFICES
mas2 16 ABBA HILLEL SILVER RD.
countryinc IL
stprinc
ein 981147233
former
changed
afs 4-NON
wksi 0
fye 1231
form 20-F
period 20241231
fy 2024
fp FY
filed 20250402
accepted 2025-04-02 16:06:00.0
prevrpt 0
detail 1
instance form20-f_htm.xml
nciks 1
aciks

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
cik Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings.
name Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date.
sic Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business.
countryba The ISO 3166-1 country of the registrant's business address.
stprba The state or province of the registrant’s business address, if field countryba is US or CA.
cityba The city of the registrant's business address.
zipba The zip code of the registrant’s business address.
bas1 The first line of the street of the registrant’s business address.
bas2 The second line of the street of the registrant’s business address.
baph The phone number of the registrant’s business address.
countryma The ISO 3166-1 country of the registrant's mailing address.
stprma The state or province of the registrant’s mailing address, if field countryma is US or CA.
cityma The city of the registrant's mailing address.
zipma The zip code of the registrant’s mailing address.
mas1 The first line of the street of the registrant’s mailing address.
mas2 The second line of the street of the registrant’s mailing address.
countryinc The ISO 3166-1 country of incorporation for the registrant.
stprinc The state or province of incorporation for the registrant, if countryinc is US or CA.
ein Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States.
former Most recent former name of the registrant, if any.
changed Date of change from the former name, if any.
afs Filer status with the SEC at the time of submission:
1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned.
wksi Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement.
fye Fiscal Year End Date, rounded to nearest month-end.
form The submission type of the registrant’s filing.
period Balance Sheet Date, rounded to nearest month-end.
fy Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8).
fp Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year.
filed The date of the registrant’s filing with the Commission.
accepted The acceptance date and time of the registrant’s filing with the Commission.
prevrpt Previous Report – TRUE indicates that the submission information was subsequently amended.
detail TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount).
instance The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol.
nciks Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing.
aciks Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information.

Numbers

adsh ddate tag value uom qtrs version segments coreg footnote
0001641172-25-002362 20231231 Additional Paid In Capital 207076000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20241231 Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options 531000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20241231 Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-002362 20241231 Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options 531000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-002362 20221231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 2130000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20241231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 4773000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20231231 Change In Fair Value Convertible Note 265000.0000 USD 4 0001641172-25-002362
0001641172-25-002362 20221231 Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest -18440000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20241231 Deposits Assets Current 3496000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20231231 Exercise Of Prefunded Warrants USD 4 0001641172-25-002362
0001641172-25-002362 20231231 Exercise Of Prefunded Warrants USD 4 0001641172-25-002362 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-002362 20241231 Exercise Of Prefunded Warrants USD 4 0001641172-25-002362
0001641172-25-002362 20241231 Exercise Of Prefunded Warrants -92000.0000 USD 4 0001641172-25-002362 Equity Components= Additional Paid In Capital;
0001641172-25-002362 20241231 Gain Loss On Sale Of Investments -12000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20221231 General And Administrative Expense 1084000.0000 USD 4 us-gaap/2024 Income Statement Location= Professional Fee;
0001641172-25-002362 20221231 Impairment On Associate USD 4 0001641172-25-002362
0001641172-25-002362 20221231 Increase Decrease In Other Accounts Payable -440000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20231231 Issuance Of Ordinary Shares Prefunded Warrants And Warrants Net Of Issuance Costs -6185000.0000 USD 4 0001641172-25-002362
0001641172-25-002362 20221231 Net Cash Provided By Used In Operating Activities -18501000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20221231 Net Income Loss USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-002362 20231231 Net Income Loss -6912000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20231231 Net Income Loss USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-002362 20241231 Net Income Loss USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-002362 20231231 Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-002362 20241231 Other Loans Payable Current 865000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20221231 Other Nonoperating Income Expense -215000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20231231 Other Nonoperating Income Expense 580000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20221231 Payments For Proceeds From Investment In Associate USD 4 0001641172-25-002362
0001641172-25-002362 20241231 Proceeds Finance Lease Interest Expense Income 70000.0000 USD 4 0001641172-25-002362 Type Of Arrangement= Standby Equity Purchase Agreement;
0001641172-25-002362 20221231 Research And Development Expense 594000.0000 USD 4 us-gaap/2024 Income Statement Location= Regulatory And Other Expenses;
0001641172-25-002362 20231231 Research And Development Expense 1001000.0000 USD 4 us-gaap/2024 Income Statement Location= Regulatory And Other Expenses;
0001641172-25-002362 20241231 Research And Development Expense 291000.0000 USD 4 us-gaap/2024 Income Statement Location= Clinical Studies;
0001641172-25-002362 20241231 Retained Earnings Accumulated Deficit -200469000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20231231 Share Based Compensation 892000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20211231 Stockholders Equity 70000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-002362 20241231 Stockholders Equity 1881000.0000 USD 0 us-gaap/2024 Title Of Individual= Onkai Inc;
0001641172-25-002362 20230731 Stock Issued During Period Shares New Issues 109583.0000 shares 0 us-gaap/2024 Award Type= Restricted Stock Units R S U;
0001641172-25-002362 20241231 Stock Issued During Period Value Exercise Of Warrants 143000.0000 USD 4 0001641172-25-002362 Equity Components= Common Stock;
0001641172-25-002362 20221231 Stock Issued During Period Value New Issues USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-002362 20221231 Stock Issued During Period Value New Issues USD 4 us-gaap/2024 Equity Components= Common Stock; Represents amounts less than $1
0001641172-25-002362 20231231 Stock Issued During Period Value Ordinary Shares Prefunded Warrants And Warrants Net Of Issuance Costs 16000.0000 USD 4 0001641172-25-002362 Equity Components= Common Stock;
0001641172-25-002362 20241231 Stock Issued During Period Value Restricted Stock Award Gross -18000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-002362 20241231 Weighted Average Number Of Diluted Shares Outstanding 930822.0000 shares 4 us-gaap/2024
0001641172-25-002362 20231231 Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options 892000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20231231 Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-002362 20231231 Cash And Cash Equivalents At Carrying Value 2861000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20231231 Common Stock Par Or Stated Value Per Share 1.8000 ILS 0 us-gaap/2024
0001641172-25-002362 20231231 Common Stock Shares Authorized 50000000.0000 shares 0 us-gaap/2024
0001641172-25-002362 20241231 Common Stock Shares Outstanding 1664884.0000 shares 0 us-gaap/2024
0001641172-25-002362 20231231 Debt Securities Available For Sale Unrealized Gain Loss 291000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20231231 Deposits Assets Current 2253000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20231231 General And Administrative Expense 1428000.0000 USD 4 us-gaap/2024 Income Statement Location= Salaries And Benefits;
0001641172-25-002362 20241231 General And Administrative Expense 48000.0000 USD 4 us-gaap/2024 Product Or Service= Administrative Service;
0001641172-25-002362 20231231 Increase Decrease In Accounts Payable Trade -681000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20231231 Investments In Affiliates Subsidiaries Associates And Joint Ventures 3265000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20231231 Liabilities And Stockholders Equity 16629000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20241231 Liabilities Current 2173000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20221231 Net Cash Provided By Used In Financing Activities 70000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20241231 Net Cash Provided By Used In Financing Activities 8786000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20221231 Operating Expenses 17651000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20231231 Operating Lease Right Of Use Asset 42000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20241231 Operating Lease Right Of Use Asset USD 0 us-gaap/2024
0001641172-25-002362 20221231 Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-002362 20231231 Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax 291000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20221231 Payments For Investment In Available For Sale Securities 2373000.0000 USD 4 0001641172-25-002362
0001641172-25-002362 20221231 Payments To Acquire Property Plant And Equipment 4000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20231231 Proceeds Finance Lease Interest Expense Income 15000.0000 USD 4 0001641172-25-002362 Type Of Arrangement= Standby Equity Purchase Agreement;
0001641172-25-002362 20221231 Proceeds From Issuance Initial Public Offering 70000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20231231 Proceeds From Issuance Initial Public Offering USD 4 us-gaap/2024
0001641172-25-002362 20230731 Proceeds From Issuance Of Common Stock 7000000.0000 USD 0 us-gaap/2024 Subsidiary Sale Of Stock= Investor Warrants;
0001641172-25-002362 20221231 Research And Development Expense 1346000.0000 USD 4 us-gaap/2024 Income Statement Location= Research And Preclinical Studies;
0001641172-25-002362 20231231 Research And Development Expense 460000.0000 USD 4 us-gaap/2024 Income Statement Location= Research And Preclinical Studies;
0001641172-25-002362 20231231 Research And Development Expense 243000.0000 USD 4 us-gaap/2024 Income Statement Location= Stock Based Compensation;
0001641172-25-002362 20241231 Research And Development Expense 2979000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20241231 Research And Development Expense 112000.0000 USD 4 us-gaap/2024 Income Statement Location= Stock Based Compensation;
0001641172-25-002362 20221231 Stockholders Equity -745000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-002362 20240831 Stock Issued During Period Shares New Issues 31566.0000 shares 0 us-gaap/2024
0001641172-25-002362 20241231 Stock Issued During Period Value Acquisitions 4926000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20241231 Stock Issued During Period Value Other 8000.0000 USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-002362 20231231 Accumulated Other Comprehensive Income Loss Net Of Tax -454000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20221231 Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options 1296000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20221231 Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options 1296000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-002362 20241231 Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-002362 20221231 Amortization Of Debt Discount Premium -2000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20231231 Assets 16629000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20241231 Assets Current 16124000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20231231 Other Asset Impairment Charges USD 4 us-gaap/2024
0001641172-25-002362 20221231 Other Asset Impairment Charges USD 4 us-gaap/2024
0001641172-25-002362 20241231 Cash And Cash Equivalents At Carrying Value 4652000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20221231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect -868000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20221231 Change In Fair Value Convertible Note USD 4 0001641172-25-002362
0001641172-25-002362 20241231 Common Stock Shares Authorized 50000000.0000 shares 0 us-gaap/2024
0001641172-25-002362 20231231 Common Stock Shares Issued 573741.0000 shares 0 us-gaap/2024
0001641172-25-002362 20241231 Common Stock Shares Issued 1664884.0000 shares 0 us-gaap/2024
0001641172-25-002362 20241231 Common Stock Value 742000.0000 USD 0 us-gaap/2024 Retroactively adjusted to reflect the 12-1 reverse split that was effected in August 2024 (see Note 11(A)(3))
0001641172-25-002362 20241231 Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest -7479000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20241231 Earnings Per Share Basic 8.0800 USD 4 us-gaap/2024 Retroactively adjusted to reflect the 12-1 reverse split that was affected in August 2024 (see Note 11(A)(3))
0001641172-25-002362 20231231 Earnings Per Share Diluted 30.0000 USD 4 us-gaap/2024
0001641172-25-002362 20231231 Financial Expenses USD 4 0001641172-25-002362
0001641172-25-002362 20241231 Financial Expenses 610000.0000 USD 4 0001641172-25-002362
0001641172-25-002362 20221231 Gain Loss On Sale Of Investments -523000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20231231 Gain Loss On Sale Of Investments -13000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20231231 General And Administrative Expense 649000.0000 USD 4 us-gaap/2024 Income Statement Location= Stock Based Compensation;
0001641172-25-002362 20231231 General And Administrative Expense 12000.0000 USD 4 us-gaap/2024 Product Or Service= Administrative Service;
0001641172-25-002362 20241231 General And Administrative Expense 389000.0000 USD 4 us-gaap/2024 Income Statement Location= Insurance And Other Expenses;
0001641172-25-002362 20241231 General And Administrative Expense 117000.0000 USD 4 us-gaap/2024 Income Statement Location= Rent And Office Maintenance Fees;
0001641172-25-002362 20241231 General And Administrative Expense 1478000.0000 USD 4 us-gaap/2024 Income Statement Location= Salaries And Benefits;
0001641172-25-002362 20231231 Income Loss From Equity Method Investments USD 4 us-gaap/2024
0001641172-25-002362 20221231 Net Income Loss USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-002362 20221231 Net Income Loss -17866000.0000 USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-002362 20241231 Net Income Loss -7517000.0000 USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-002362 20231231 Operating Expenses 7492000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20221231 Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax -574000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20231231 Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax 291000.0000 USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-002362 20241231 Other Nonoperating Income Expense 516000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20231231 Payments For Proceeds From Investment In Associate 1500000.0000 USD 4 0001641172-25-002362
0001641172-25-002362 20241231 Payments For Proceeds From Investment In Associate USD 4 0001641172-25-002362
0001641172-25-002362 20231231 Payments For Proceeds From Investment In Convertible Note USD 4 0001641172-25-002362
0001641172-25-002362 20221231 Payments Of Stock Issuance Costs 2000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20221231 Proceeds From Issuance Of Common Stock USD 4 us-gaap/2024
0001641172-25-002362 20221231 Proceeds From Issuance Of Common Stock 100000.0000 USD 4 us-gaap/2024 Type Of Arrangement= New Sales Agreement;
0001641172-25-002362 20230731 Proceeds From Issuance Of Common Stock 4400000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20231231 Proceeds From Issuance Of Common Stock USD 4 us-gaap/2024
0001641172-25-002362 20241231 Proceeds From Issuance Of Common Stock 4386000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20211231 Stockholders Equity 30497000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20231231 Proceeds From Sale Of Available For Sale Securities Debt 8633000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20241231 Research And Development Expense 3300000.0000 USD 4 us-gaap/2024 Regulatory Asset= Deferred Income Tax Charges;
0001641172-25-002362 20221231 Shares Outstanding 294325.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-002362 20221231 Stockholders Equity 200138000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-002362 20241231 Stockholders Equity 16327000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20241231 Stockholders Equity 216470000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-002362 20241231 Stock Issued During Period Shares Exercise Of Warrants 293333.0000 shares 4 0001641172-25-002362 Equity Components= Common Stock;
0001641172-25-002362 20221231 Stock Issued During Period Shares New Issues 643.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-002362 20221231 Stock Issued During Period Shares New Issues 643.0000 shares 4 us-gaap/2024 Type Of Arrangement= New Sales Agreement;
0001641172-25-002362 20221231 Stock Issued During Period Value New Issues USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-002362 20231231 Stock Issued During Period Value Ordinary Shares Prefunded Warrants And Warrants Net Of Issuance Costs USD 4 0001641172-25-002362 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-002362 20241231 Stock Issued During Period Value Other 62000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-002362 20221231 Weighted Average Number Of Shares Outstanding Basic 139682.0000 shares 4 us-gaap/2024
0001641172-25-002362 20231231 Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options 892000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-002362 20231231 Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-002362 20241231 Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-002362 20211231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 2998000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20231231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 2978000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20231231 Commitments And Contingencies USD 0 us-gaap/2024
0001641172-25-002362 20241231 Commitments And Contingencies USD 0 us-gaap/2024
0001641172-25-002362 20221231 Decrease In Shortterm Deposits USD 4 0001641172-25-002362
0001641172-25-002362 20231231 Decrease In Shortterm Deposits 53000.0000 USD 4 0001641172-25-002362
0001641172-25-002362 20221231 Depreciation And Amortization 35000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20231231 Depreciation And Amortization 31000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20221231 Earnings Per Share Diluted 127.8000 USD 4 us-gaap/2024
0001641172-25-002362 20241231 Earnings Per Share Diluted 8.0800 USD 4 us-gaap/2024
0001641172-25-002362 20241231 Increase Decrease In Other Accounts Payable 35000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20221231 Interest Paid Net 297000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20241231 Liabilities And Stockholders Equity 18500000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20241231 Net Cash Provided By Used In Investing Activities -1111000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20231231 Net Cash Provided By Used In Operating Activities -6137000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20241231 Net Cash Provided By Used In Operating Activities -5880000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20231231 Net Income Loss USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-002362 20241231 Net Income Loss USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-002362 20241231 Operating Expenses 2485000.0000 USD 4 us-gaap/2024 Title Of Individual= Onkai Inc;
0001641172-25-002362 20241231 Other Asset Impairment Charges 1145000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20241231 Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax 38000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20231231 Other Loans Payable Current 871000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20221231 Payments To Acquire Businesses Gross USD 4 us-gaap/2024
0001641172-25-002362 20241231 Proceeds From Issuance Initial Public Offering USD 4 us-gaap/2024
0001641172-25-002362 20241231 Proceeds From Issuance Of Common Stock 5000000.0000 USD 4 us-gaap/2024 Equity Components= Common Stock; Type Of Arrangement= Cayman Islands Exempt Limited Partnership;
0001641172-25-002362 20231231 Research And Development Expense 616000.0000 USD 4 us-gaap/2024 Income Statement Location= Clinical Studies;
0001641172-25-002362 20241231 Research And Development Expense 696000.0000 USD 4 us-gaap/2024 Income Statement Location= Chemistry And Formulation Studies;
0001641172-25-002362 20241231 Restricted Cash Current 121000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20241231 Share Based Compensation 531000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20221231 Stockholders Equity 13423000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20241231 Stockholders Equity -200469000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-002362 20231231 Stock Issued During Period Shares Ordinary Shares Prefunded Warrants And Warrants Net Of Issuance Costs 31667.0000 shares 4 0001641172-25-002362 Equity Components= Common Stock; See also Note 11(A)(4)
0001641172-25-002362 20221231 Stock Issued During Period Value New Issues 70000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20231231 Weighted Average Number Of Shares Outstanding Basic 230795.0000 shares 4 us-gaap/2024
0001641172-25-002362 20241231 Weighted Average Number Of Shares Outstanding Basic 930822.0000 shares 4 us-gaap/2024
0001641172-25-002362 20221231 Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-002362 20241231 Assets 18500000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20241231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect 1795000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20241231 Common Stock Par Or Stated Value Per Share 1.8000 ILS 0 us-gaap/2024
0001641172-25-002362 20231231 Common Stock Value 209000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20231231 Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest -6621000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20241231 Conversion Of Convertible Note Into Investment In Associate USD 4 0001641172-25-002362
0001641172-25-002362 20221231 Debt Securities Available For Sale Unrealized Gain Loss -574000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20231231 Exercise Of Prefunded Warrants 123000.0000 USD 4 0001641172-25-002362 Equity Components= Common Stock;
0001641172-25-002362 20241231 Exercise Of Prefunded Warrants 92000.0000 USD 4 0001641172-25-002362 Equity Components= Common Stock;
0001641172-25-002362 20231231 Exercise Of Prefunded Warrants Shares 247749.0000 shares 4 0001641172-25-002362 Equity Components= Common Stock;
0001641172-25-002362 20221231 General And Administrative Expense 4656000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20221231 General And Administrative Expense 1094000.0000 USD 4 us-gaap/2024 Income Statement Location= Insurance And Other Expenses;
0001641172-25-002362 20231231 General And Administrative Expense 677000.0000 USD 4 us-gaap/2024 Income Statement Location= Insurance And Other Expenses;
0001641172-25-002362 20231231 General And Administrative Expense 261000.0000 USD 4 us-gaap/2024 Income Statement Location= Rent And Office Maintenance Fees;
0001641172-25-002362 20221231 Income Loss From Equity Method Investments USD 4 us-gaap/2024
0001641172-25-002362 20231231 Increase Decrease In Other Accounts Payable 468000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20231231 Interest Paid Net 376000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20231231 Net Income Loss -6912000.0000 USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-002362 20241231 Net Income Loss USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-002362 20241231 Operating Expenses 6278000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20221231 Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-002362 20231231 Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-002362 20231231 Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-002362 20241231 Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax 38000.0000 USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-002362 20241231 Payments For Investment In Available For Sale Securities 5115000.0000 USD 4 0001641172-25-002362
0001641172-25-002362 20241231 Proceeds From Sale Of Available For Sale Securities Debt 5504000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20221231 Research And Development Expense 12995000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20221231 Research And Development Expense 1692000.0000 USD 4 us-gaap/2024 Income Statement Location= Salaries;
0001641172-25-002362 20221231 Research And Development Expense 383000.0000 USD 4 us-gaap/2024 Income Statement Location= Stock Based Compensation;
0001641172-25-002362 20241231 Research And Development Expense 255000.0000 USD 4 us-gaap/2024 Income Statement Location= Research And Preclinical Studies;
0001641172-25-002362 20241231 Research And Development Expense 982000.0000 USD 4 us-gaap/2024 Income Statement Location= Salaries;
0001641172-25-002362 20231231 Restricted Cash Current 117000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20221231 Share Based Compensation 1296000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20211231 Shares Outstanding 293682.0000 shares 0 us-gaap/2024 Equity Components= Common Stock; Retroactively adjusted to reflect the 12-1 reverse split that was effected in August 2024 (see Note 11(A)(3))
0001641172-25-002362 20231231 Stockholders Equity -454000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-002362 20230731 Stock Issued During Period Shares New Issues 31666.0000 shares 0 us-gaap/2024
0001641172-25-002362 20241231 Stock Issued During Period Value Acquisitions USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-002362 20221231 Stock Issued During Period Value New Issues 70000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-002362 20231231 Stock Issued During Period Value Ordinary Shares Prefunded Warrants And Warrants Net Of Issuance Costs 6185000.0000 USD 4 0001641172-25-002362
0001641172-25-002362 20241231 Stock Issued During Period Value Other 70000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20221231 Weighted Average Number Of Diluted Shares Outstanding 139682.0000 shares 4 us-gaap/2024
0001641172-25-002362 20241231 Accumulated Other Comprehensive Income Loss Net Of Tax -416000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20241231 Additional Paid In Capital 216470000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20231231 Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-002362 20231231 Assets Current 13239000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20231231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect 848000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20221231 Conversion Of Convertible Note Into Investment In Associate USD 4 0001641172-25-002362
0001641172-25-002362 20241231 Depreciation And Amortization 83000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20231231 Earnings Per Share Basic 30.0000 USD 4 us-gaap/2024
0001641172-25-002362 20241231 Exercise Of Prefunded Warrants Shares 186723.0000 shares 4 0001641172-25-002362 Equity Components= Common Stock;
0001641172-25-002362 20241231 General And Administrative Expense 3299000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20241231 General And Administrative Expense 896000.0000 USD 4 us-gaap/2024 Income Statement Location= Professional Fee;
0001641172-25-002362 20241231 Impairment On Associate 1145000.0000 USD 4 0001641172-25-002362
0001641172-25-002362 20241231 Income Loss From Equity Method Investments 7000.0000 USD 4 us-gaap/2024 See also Note 7
0001641172-25-002362 20241231 Increase Decrease In Accounts And Other Receivables 192000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20241231 Interest Paid Net 503000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20231231 Liabilities Current 2750000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20241231 Marketable Securities Current 7183000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20231231 Net Cash Provided By Used In Investing Activities 800000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20221231 Net Income Loss USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-002362 20231231 Net Income Loss USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-002362 20241231 Net Income Loss -7517000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20241231 Net Income Loss -2537000.0000 USD 4 us-gaap/2024 Title Of Individual= Onkai Inc;
0001641172-25-002362 20241231 Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-002362 20231231 Other Receivables Net Current 480000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20231231 Payments For Proceeds From Other Deposits 2200000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20241231 Payments For Proceeds From Other Deposits 1250000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20231231 Payments To Acquire Property Plant And Equipment USD 4 us-gaap/2024
0001641172-25-002362 20241231 Payments To Acquire Property Plant And Equipment USD 4 us-gaap/2024
0001641172-25-002362 20231231 Property Plant And Equipment Net 83000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20241231 Property Plant And Equipment Net USD 0 us-gaap/2024
0001641172-25-002362 20221231 Research And Development Expense 2448000.0000 USD 4 us-gaap/2024 Income Statement Location= Chemistry And Formulation Studies;
0001641172-25-002362 20221231 Research And Development Expense 6532000.0000 USD 4 us-gaap/2024 Income Statement Location= Clinical Studies;
0001641172-25-002362 20231231 Research And Development Expense 573000.0000 USD 4 us-gaap/2024 Income Statement Location= Chemistry And Formulation Studies;
0001641172-25-002362 20211231 Stockholders Equity -168174000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-002362 20231231 Stockholders Equity 13879000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20231231 Stockholders Equity 207076000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-002362 20241231 Stock Issued During Period Shares Acquisitions 558775.0000 shares 4 us-gaap/2024 Equity Components= Common Stock; See also Note 11(A)(5)
0001641172-25-002362 20241231 Stock Issued During Period Shares New Issues 574559.0000 shares 4 us-gaap/2024 Equity Components= Common Stock; Type Of Arrangement= Cayman Islands Exempt Limited Partnership;
0001641172-25-002362 20241231 Stock Issued During Period Value Acquisitions USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-002362 20231231 Warrants Net Of Issuance Costs 756000.0000 USD 4 0001641172-25-002362
0001641172-25-002362 20241231 Accounts Payable Current 1308000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20221231 Payments For Proceeds From Other Deposits USD 4 us-gaap/2024
0001641172-25-002362 20241231 Payments To Acquire Businesses Gross 250000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20231231 Other Assets Noncurrent USD 0 us-gaap/2024
0001641172-25-002362 20241231 Other Assets Noncurrent 257000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20231231 Accounts Payable Current 1879000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20221231 Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-002362 20221231 Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-002362 20241231 Assets Current 105000.0000 USD 0 us-gaap/2024 Title Of Individual= Onkai Inc;
0001641172-25-002362 20241231 Assets Noncurrent 3000.0000 USD 0 us-gaap/2024 Title Of Individual= Onkai Inc;
0001641172-25-002362 20231231 Common Stock Shares Outstanding 573741.0000 shares 0 us-gaap/2024
0001641172-25-002362 20241231 Debt Securities Available For Sale Unrealized Gain Loss 38000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20241231 Decrease In Shortterm Deposits -7000.0000 USD 4 0001641172-25-002362
0001641172-25-002362 20221231 Earnings Per Share Basic 127.8000 USD 4 us-gaap/2024
0001641172-25-002362 20231231 Exercise Of Prefunded Warrants -123000.0000 USD 4 0001641172-25-002362 Equity Components= Additional Paid In Capital;
0001641172-25-002362 20231231 Exercise Of Prefunded Warrants USD 4 0001641172-25-002362 Equity Components= Retained Earnings;
0001641172-25-002362 20221231 General And Administrative Expense 1164000.0000 USD 4 us-gaap/2024 Income Statement Location= Salaries And Benefits;
0001641172-25-002362 20221231 General And Administrative Expense 913000.0000 USD 4 us-gaap/2024 Income Statement Location= Stock Based Compensation;
0001641172-25-002362 20231231 General And Administrative Expense 908000.0000 USD 4 us-gaap/2024 Income Statement Location= Professional Fee;
0001641172-25-002362 20231231 Impairment On Associate USD 4 0001641172-25-002362
0001641172-25-002362 20241231 Issuance Of Ordinary Shares Prefunded Warrants And Warrants Net Of Issuance Costs -4400000.0000 USD 4 0001641172-25-002362 See also Note 11(A)(4)
0001641172-25-002362 20241231 Liabilities Current 324000.0000 USD 0 us-gaap/2024 Title Of Individual= Onkai Inc;
0001641172-25-002362 20221231 Net Cash Provided By Used In Investing Activities 17563000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20221231 Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax -574000.0000 USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-002362 20241231 Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-002362 20241231 Other Receivables Net Current 672000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20231231 Payments For Investment In Available For Sale Securities 4133000.0000 USD 4 0001641172-25-002362
0001641172-25-002362 20221231 Payments For Proceeds From Investment In Convertible Note 1500000.0000 USD 4 0001641172-25-002362
0001641172-25-002362 20241231 Payments For Proceeds From Investment In Convertible Note USD 4 0001641172-25-002362
0001641172-25-002362 20231231 Proceeds Finance Lease Interest Expense Income 6000.0000 USD 4 0001641172-25-002362
0001641172-25-002362 20241231 Proceeds Finance Lease Interest Expense Income 1000.0000 USD 4 0001641172-25-002362
0001641172-25-002362 20231231 Research And Development Expense 676000.0000 USD 4 us-gaap/2024 Income Statement Location= Salaries;
0001641172-25-002362 20231231 Retained Earnings Accumulated Deficit -192952000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20231231 Shares Outstanding 573741.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-002362 20221231 Stockholders Equity 70000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-002362 20221231 Stockholders Equity -186040000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-002362 20231231 Stockholders Equity -192952000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-002362 20241231 Stock Issued During Period Value Acquisitions 272000.0000 USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-002362 20241231 Stock Issued During Period Value Exercise Of Warrants 4257000.0000 USD 4 0001641172-25-002362 Equity Components= Additional Paid In Capital;
0001641172-25-002362 20231231 Stock Issued During Period Value Ordinary Shares Prefunded Warrants And Warrants Net Of Issuance Costs 6169000.0000 USD 4 0001641172-25-002362 Equity Components= Additional Paid In Capital;
0001641172-25-002362 20231231 Stock Issued During Period Value Ordinary Shares Prefunded Warrants And Warrants Net Of Issuance Costs USD 4 0001641172-25-002362 Equity Components= Retained Earnings;
0001641172-25-002362 20241231 Stock Issued During Period Value Restricted Stock Award Gross 18000.0000 USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-002362 20231231 Weighted Average Number Of Diluted Shares Outstanding 230795.0000 shares 4 us-gaap/2024
0001641172-25-002362 20231231 Amortization Of Debt Discount Premium 19000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20241231 Amortization Of Debt Discount Premium -17000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20231231 Assets Noncurrent 3390000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20241231 Assets Noncurrent 2376000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20231231 Conversion Of Convertible Note Into Investment In Associate 1765000.0000 USD 4 0001641172-25-002362
0001641172-25-002362 20221231 Financial Expenses USD 4 0001641172-25-002362
0001641172-25-002362 20221231 General And Administrative Expense 401000.0000 USD 4 us-gaap/2024 Income Statement Location= Rent And Office Maintenance Fees;
0001641172-25-002362 20231231 General And Administrative Expense 3923000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20241231 General And Administrative Expense 419000.0000 USD 4 us-gaap/2024 Income Statement Location= Stock Based Compensation;
0001641172-25-002362 20221231 Increase Decrease In Accounts And Other Receivables -300000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20231231 Increase Decrease In Accounts And Other Receivables -345000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20221231 Increase Decrease In Accounts Payable Trade -2311000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20241231 Increase Decrease In Accounts Payable Trade -571000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20241231 Investments In Affiliates Subsidiaries Associates And Joint Ventures 2119000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20231231 Marketable Securities Current 7528000.0000 USD 0 us-gaap/2024
0001641172-25-002362 20231231 Net Cash Provided By Used In Financing Activities 6185000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20221231 Net Income Loss -17866000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20221231 Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-002362 20241231 Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-002362 20231231 Payments To Acquire Businesses Gross USD 4 us-gaap/2024
0001641172-25-002362 20221231 Proceeds Finance Lease Interest Expense Income -36000.0000 USD 4 0001641172-25-002362
0001641172-25-002362 20221231 Proceeds From Sale Of Available For Sale Securities Debt 21440000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20231231 Research And Development Expense 3569000.0000 USD 4 us-gaap/2024
0001641172-25-002362 20241231 Research And Development Expense 643000.0000 USD 4 us-gaap/2024 Income Statement Location= Regulatory And Other Expenses;
0001641172-25-002362 20241231 Shares Outstanding 1664884.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-002362 20211231 Stockholders Equity -171000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-002362 20211231 Stockholders Equity 198772000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-002362 20231231 Stockholders Equity 209000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-002362 20241231 Stockholders Equity -416000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-002362 20241231 Stockholders Equity 742000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-002362 20241231 Stock Issued During Period Shares Other 15784.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-002362 20241231 Stock Issued During Period Shares Restricted Stock Award Gross 36528.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-002362 20241231 Stock Issued During Period Value Acquisitions 4654000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-002362 20241231 Stock Issued During Period Value Exercise Of Warrants 4400000.0000 USD 4 0001641172-25-002362
0001641172-25-002362 20241231 Stock Issued During Period Value Restricted Stock Award Gross USD 4 us-gaap/2024

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
ddate The end date for the data value, rounded to the nearest month end.
qtrs The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value.
uom The unit of measure for the value.
segments Tags used to represent axis and member reporting.
coreg If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity.
value The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point.
footnote The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank.

Tags

tag version custom abstract datatype iord crdr tlabel doc
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest us-gaap/2024 0 0 monetary D C Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.
Amortization Of Debt Discount Premium us-gaap/2024 0 0 monetary D D Amortization of Debt Discount (Premium) Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
Assets Current us-gaap/2024 0 0 monetary I D Assets, Current Amount of asset recognized for present right to economic benefit, classified as current.
Increase Decrease In Accounts Payable Trade us-gaap/2024 0 0 monetary D D Increase (Decrease) in Accounts Payable, Trade Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.
Payments For Proceeds From Investment In Convertible Note 0001641172-25-002362 1 0 monetary D C PaymentsForProceedsFromInvestmentInConvertibleNote Payments for proceeds from investment in convertible note.
Depreciation And Amortization us-gaap/2024 0 0 monetary D D Depreciation, Depletion and Amortization, Nonproduction The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
Payments To Acquire Property Plant And Equipment us-gaap/2024 0 0 monetary D C Payments to Acquire Property, Plant, and Equipment The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
Stock Issued During Period Shares Restricted Stock Award Gross us-gaap/2024 0 0 shares D Stock Issued During Period, Shares, Restricted Stock Award, Gross Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.
Liabilities And Stockholders Equity us-gaap/2024 0 0 monetary I C Liabilities and Equity Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax us-gaap/2024 0 0 monetary D C OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.
Payments For Proceeds From Other Deposits us-gaap/2024 0 0 monetary D C Payments for (Proceeds from) Other Deposits Amount of cash (inflow) outflow from deposits classified as other.
Retained Earnings Accumulated Deficit us-gaap/2024 0 0 monetary I C Retained Earnings (Accumulated Deficit) Amount of accumulated undistributed earnings (deficit).
Decrease In Shortterm Deposits 0001641172-25-002362 1 0 monetary D C DecreaseInShorttermDeposits Decrease in short term deposits.
Payments For Investment In Available For Sale Securities 0001641172-25-002362 1 0 monetary D C PaymentsForInvestmentInAvailableForSaleSecurities Payments for investment in available for sale securities.
Stock Issued During Period Shares Exercise Of Warrants 0001641172-25-002362 1 0 shares D Exercise of Warrants, shares Exercise of warrants, shares
Financial Expenses 0001641172-25-002362 1 0 monetary D D Financial expenses related to SEPA Financial expenses.
Additional Paid In Capital us-gaap/2024 0 0 monetary I C Additional Paid in Capital Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.
Common Stock Par Or Stated Value Per Share us-gaap/2024 0 0 perShare I Common Stock, Par or Stated Value Per Share Face amount or stated value per share of common stock.
Common Stock Shares Outstanding us-gaap/2024 0 0 shares I Common Stock, Shares, Outstanding Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
Investments In Affiliates Subsidiaries Associates And Joint Ventures us-gaap/2024 0 0 monetary I D Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures Amount of investment in equity method investee and investment in and advance to affiliate.
Net Income Loss us-gaap/2024 0 0 monetary D C Net Income (Loss) Attributable to Parent The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Restricted Cash Current us-gaap/2024 0 0 monetary I D Restricted Cash, Current Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
Stockholders Equity us-gaap/2024 0 0 monetary I C Equity, Attributable to Parent Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
Weighted Average Number Of Diluted Shares Outstanding us-gaap/2024 0 0 shares D Weighted Average Number of Shares Outstanding, Diluted The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Liabilities Current us-gaap/2024 0 0 monetary I C Liabilities, Current Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
Accumulated Other Comprehensive Income Loss Net Of Tax us-gaap/2024 0 0 monetary I C Accumulated Other Comprehensive Income (Loss), Net of Tax Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.
Assets us-gaap/2024 0 0 monetary I D Assets Amount of asset recognized for present right to economic benefit.
Common Stock Shares Issued us-gaap/2024 0 0 shares I Common Stock, Shares, Issued Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
Earnings Per Share Diluted us-gaap/2024 0 0 perShare D Earnings Per Share, Diluted The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
Increase Decrease In Accounts And Other Receivables us-gaap/2024 0 0 monetary D C Increase (Decrease) in Accounts and Other Receivables The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.
Operating Lease Right Of Use Asset us-gaap/2024 0 0 monetary I D Operating Lease, Right-of-Use Asset Amount of lessee's right to use underlying asset under operating lease.
Other Assets Noncurrent us-gaap/2024 0 0 monetary I D Other Assets, Noncurrent Amount of noncurrent assets classified as other.
Change In Fair Value Convertible Note 0001641172-25-002362 1 0 monetary D C ChangeInFairValueConvertibleNote Change in fair value convertible note.
Conversion Of Convertible Note Into Investment In Associate 0001641172-25-002362 1 0 monetary D C Conversion of convertible note into investment in associate Conversion of convertible note into investment in associate.
Exercise Of Prefunded Warrants 0001641172-25-002362 1 0 monetary D C Exercise of Pre-funded warrants Exercise of Pre-funded warrants.
Payments For Proceeds From Investment In Associate 0001641172-25-002362 1 0 monetary D C PaymentsForProceedsFromInvestmentInAssociate payments for proceeds from investment in associate.
Marketable Securities Current us-gaap/2024 0 0 monetary I D Marketable Securities, Current Amount of investment in marketable security, classified as current.
Share Based Compensation us-gaap/2024 0 0 monetary D D Share-Based Payment Arrangement, Noncash Expense Amount of noncash expense for share-based payment arrangement.
Stock Issued During Period Value Acquisitions us-gaap/2024 0 0 monetary D C Stock Issued During Period, Value, Acquisitions Value of stock issued pursuant to acquisitions during the period.
Cash And Cash Equivalents At Carrying Value us-gaap/2024 0 0 monetary I D Cash and Cash Equivalents, at Carrying Value Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
Exercise Of Prefunded Warrants Shares 0001641172-25-002362 1 0 shares D Exercise of Pre-funded warrants, shares Exercise of Pre-funded warrants, shares.
Other Loans Payable Current us-gaap/2024 0 0 monetary I C Other Loans Payable, Current Amount of long-term loans classified as other, payable within one year or the operating cycle, if longer.
Payments Of Stock Issuance Costs us-gaap/2024 0 0 monetary D C Payments of Stock Issuance Costs The cash outflow for cost incurred directly with the issuance of an equity security.
Impairment On Associate 0001641172-25-002362 1 0 monetary D D Impairment on associate
Deposits Assets Current us-gaap/2024 0 0 monetary I D Deposits Assets, Current Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.
Common Stock Value us-gaap/2024 0 0 monetary I C Common Stock, Value, Issued Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
Net Cash Provided By Used In Operating Activities us-gaap/2024 0 0 monetary D Net Cash Provided by (Used in) Operating Activities Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Operating Expenses us-gaap/2024 0 0 monetary D D Operating Expenses Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
Proceeds From Issuance Initial Public Offering us-gaap/2024 0 0 monetary D D Proceeds from Issuance Initial Public Offering The cash inflow associated with the amount received from entity's first offering of stock to the public.
Stock Issued During Period Shares Other us-gaap/2024 0 0 shares D Stock Issued During Period, Shares, Other Number of shares of stock issued attributable to transactions classified as other.
Proceeds Finance Lease Interest Expense Income 0001641172-25-002362 1 0 monetary D D Finance expenses (income) Finance expenses (income).
Debt Securities Available For Sale Unrealized Gain Loss us-gaap/2024 0 0 monetary D C Debt Securities, Available-for-Sale, Unrealized Gain (Loss) Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
General And Administrative Expense us-gaap/2024 0 0 monetary D D General and Administrative Expense The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
Income Loss From Equity Method Investments us-gaap/2024 0 0 monetary D C Income (Loss) from Equity Method Investments Amount of income (loss) for proportionate share of equity method investee's income (loss).
Research And Development Expense us-gaap/2024 0 0 monetary D D Research and Development Expense Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.
Stock Issued During Period Shares New Issues us-gaap/2024 0 0 shares D Stock Issued During Period, Shares, New Issues Number of new stock issued during the period.
Stock Issued During Period Value Exercise Of Warrants 0001641172-25-002362 1 0 monetary D C Exercise of Warrants Exercise of warrants, value.
Assets Noncurrent us-gaap/2024 0 0 monetary I D Assets, Noncurrent Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.
Accounts Payable Current us-gaap/2024 0 0 monetary I C Accounts Payable, Current Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2024 0 0 monetary D D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Commitments And Contingencies us-gaap/2024 0 0 monetary I C Commitments and Contingencies Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
Common Stock Shares Authorized us-gaap/2024 0 0 shares I Common Stock, Shares Authorized The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
Interest Paid Net us-gaap/2024 0 0 monetary D C Interest Paid, Excluding Capitalized Interest, Operating Activities Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
Net Cash Provided By Used In Financing Activities us-gaap/2024 0 0 monetary D D Net Cash Provided by (Used in) Financing Activities Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Other Asset Impairment Charges us-gaap/2024 0 0 monetary D D Other Asset Impairment Charges The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.
Payments To Acquire Businesses Gross us-gaap/2024 0 0 monetary D C Payments to Acquire Businesses, Gross The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.
Proceeds From Sale Of Available For Sale Securities Debt us-gaap/2024 0 0 monetary D D Proceeds from Sale of Debt Securities, Available-for-Sale Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
Shares Outstanding us-gaap/2024 0 0 shares I Shares, Outstanding Number of shares issued which are neither cancelled nor held in the treasury.
Stock Issued During Period Value Restricted Stock Award Gross us-gaap/2024 0 0 monetary D C Stock Issued During Period, Value, Restricted Stock Award, Gross Aggregate value of stock related to Restricted Stock Awards issued during the period.
Warrants Net Of Issuance Costs 0001641172-25-002362 1 0 monetary D C Warrants net of issuance costs Warrants net of issuance costs.
Net Cash Provided By Used In Investing Activities us-gaap/2024 0 0 monetary D D Net Cash Provided by (Used in) Investing Activities Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations us-gaap/2024 0 0 monetary I D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Earnings Per Share Basic us-gaap/2024 0 0 perShare D Earnings Per Share, Basic The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
Gain Loss On Sale Of Investments us-gaap/2024 0 0 monetary D C Gain (Loss) on Sale of Investments The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.
Other Nonoperating Income Expense us-gaap/2024 0 0 monetary D C Other Nonoperating Income (Expense) Amount of income (expense) related to nonoperating activities, classified as other.
Other Receivables Net Current us-gaap/2024 0 0 monetary I D Other Receivables, Net, Current Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.
Proceeds From Issuance Of Common Stock us-gaap/2024 0 0 monetary D D Proceeds from Issuance of Common Stock The cash inflow from the additional capital contribution to the entity.
Stock Issued During Period Value New Issues us-gaap/2024 0 0 monetary D C Stock Issued During Period, Value, New Issues Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
Stock Issued During Period Shares Ordinary Shares Prefunded Warrants And Warrants Net Of Issuance Costs 0001641172-25-002362 1 0 shares D Issuance of ordinary shares, pre-funded warrants, and warrants net of issuance costs, shares Stock issued during period shares ordinary shares prefunded warrants and warrants net of issuance costs.
Stock Issued During Period Value Ordinary Shares Prefunded Warrants And Warrants Net Of Issuance Costs 0001641172-25-002362 1 0 monetary D C Issuance of ordinary shares, pre-funded warrants, and warrants net of issuance costs of $756 thousand Stock issued during period value ordinary shares prefunded warrants and warrants net of issuance costs.
Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options us-gaap/2024 0 0 monetary D C APIC, Share-Based Payment Arrangement, Recognition and Exercise Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement.
Increase Decrease In Other Accounts Payable us-gaap/2024 0 0 monetary D D Increase (Decrease) in Other Accounts Payable Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.
Property Plant And Equipment Net us-gaap/2024 0 0 monetary I D Property, Plant and Equipment, Net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
Stock Issued During Period Shares Acquisitions us-gaap/2024 0 0 shares D Stock Issued During Period, Shares, Acquisitions Number of shares of stock issued during the period pursuant to acquisitions.
Stock Issued During Period Value Other us-gaap/2024 0 0 monetary D C Stock Issued During Period, Value, Other Value of shares of stock issued attributable to transactions classified as other.
Weighted Average Number Of Shares Outstanding Basic us-gaap/2024 0 0 shares D Weighted Average Number of Shares Outstanding, Basic Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Issuance Of Ordinary Shares Prefunded Warrants And Warrants Net Of Issuance Costs 0001641172-25-002362 1 0 monetary D C IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts Issuance of ordinary shares, pre-funded warrants, and warrants net of issuance costs.

Description
Field Name Field Description
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
custom 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns.
abstract 1 if the tag is not used to represent a numeric fact.
datatype If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag.
iord If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration.
crdr If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL.
tlabel If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here.
doc The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL.

Presentation of Statements

adsh report line stmt inpth rfile tag version plabel negating
0001641172-25-002362 2 3 BS 0 H Cash And Cash Equivalents At Carrying Value us-gaap/2024 Cash and cash equivalents 0
0001641172-25-002362 2 4 BS 0 H Restricted Cash Current us-gaap/2024 Restricted cash 0
0001641172-25-002362 2 5 BS 0 H Deposits Assets Current us-gaap/2024 Short-term deposits 0
0001641172-25-002362 2 6 BS 0 H Marketable Securities Current us-gaap/2024 Marketable debt securities 0
0001641172-25-002362 2 7 BS 0 H Other Receivables Net Current us-gaap/2024 Other receivables 0
0001641172-25-002362 2 8 BS 0 H Assets Current us-gaap/2024 Total current assets 0
0001641172-25-002362 2 9 BS 0 H Operating Lease Right Of Use Asset us-gaap/2024 Operating lease right-of-use assets 0
0001641172-25-002362 2 10 BS 0 H Property Plant And Equipment Net us-gaap/2024 Property and equipment, net 0
0001641172-25-002362 2 11 BS 0 H Investments In Affiliates Subsidiaries Associates And Joint Ventures us-gaap/2024 Investment in associate at fair value 0
0001641172-25-002362 2 12 BS 0 H Other Assets Noncurrent us-gaap/2024 Loan to associate 0
0001641172-25-002362 2 13 BS 0 H Assets Noncurrent us-gaap/2024 Total non-current assets 0
0001641172-25-002362 2 14 BS 0 H Assets us-gaap/2024 Total assets 0
0001641172-25-002362 2 17 BS 0 H Accounts Payable Current us-gaap/2024 Trade payables 0
0001641172-25-002362 2 18 BS 0 H Other Loans Payable Current us-gaap/2024 Other payables 0
0001641172-25-002362 2 19 BS 0 H Liabilities Current us-gaap/2024 Total current liabilities 0
0001641172-25-002362 2 20 BS 0 H Commitments And Contingencies us-gaap/2024 Commitments and contingencies liabilities 0
0001641172-25-002362 2 22 BS 0 H Common Stock Value us-gaap/2024 Ordinary shares, par value NIS 1.80 per share; Authorized 50,000,000 shares; Issued and outstanding: 1,664,884 and 573,741 shares as of December 31, 2024 and December 31, 2023, respectively 0
0001641172-25-002362 2 23 BS 0 H Additional Paid In Capital us-gaap/2024 Additional paid-in capital 0
0001641172-25-002362 2 24 BS 0 H Accumulated Other Comprehensive Income Loss Net Of Tax us-gaap/2024 Accumulated other comprehensive loss 0
0001641172-25-002362 2 25 BS 0 H Retained Earnings Accumulated Deficit us-gaap/2024 Accumulated deficit 0
0001641172-25-002362 2 26 BS 0 H Stockholders Equity us-gaap/2024 Total stockholders equity 0
0001641172-25-002362 2 27 BS 0 H Liabilities And Stockholders Equity us-gaap/2024 Total liabilities and stockholders equity 0
0001641172-25-002362 3 1 BS 1 H Common Stock Par Or Stated Value Per Share us-gaap/2024 Ordinary shares, par value 0
0001641172-25-002362 3 2 BS 1 H Common Stock Shares Authorized us-gaap/2024 Ordinary shares, authorized 0
0001641172-25-002362 3 3 BS 1 H Common Stock Shares Issued us-gaap/2024 Ordinary shares, issued 0
0001641172-25-002362 3 4 BS 1 H Common Stock Shares Outstanding us-gaap/2024 Ordinary shares, outstanding 0
0001641172-25-002362 4 1 IS 0 H Research And Development Expense us-gaap/2024 Research and development expenses 0
0001641172-25-002362 4 2 IS 0 H General And Administrative Expense us-gaap/2024 General and administrative expenses 0
0001641172-25-002362 4 3 IS 0 H Operating Expenses us-gaap/2024 Total operating loss 0
0001641172-25-002362 4 4 IS 0 H Other Nonoperating Income Expense us-gaap/2024 Financial loss (income), net 1
0001641172-25-002362 4 5 IS 0 H Financial Expenses 0001641172-25-002362 Financial expenses related to SEPA 0
0001641172-25-002362 4 6 IS 0 H Impairment On Associate 0001641172-25-002362 Impairment on associate 0
0001641172-25-002362 4 7 IS 0 H Net Income Loss us-gaap/2024 Net loss 1
0001641172-25-002362 4 8 IS 0 H Earnings Per Share Basic us-gaap/2024 Basic, net loss per share 0
0001641172-25-002362 4 9 IS 0 H Earnings Per Share Diluted us-gaap/2024 Diluted, net loss per share 0
0001641172-25-002362 4 10 IS 0 H Weighted Average Number Of Shares Outstanding Basic us-gaap/2024 Weighted average number of shares outstanding used in computing net loss per share, basic 0
0001641172-25-002362 4 11 IS 0 H Weighted Average Number Of Diluted Shares Outstanding us-gaap/2024 Weighted average number of shares outstanding used in computing net loss per share, diluted 0
0001641172-25-002362 6 1 CI 0 H Net Income Loss us-gaap/2024 Net loss 1
0001641172-25-002362 6 3 CI 0 H Debt Securities Available For Sale Unrealized Gain Loss us-gaap/2024 Net unrealized loss (gain) on available for sale securities 1
0001641172-25-002362 6 4 CI 0 H Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest us-gaap/2024 Comprehensive loss 1
0001641172-25-002362 7 9 EQ 0 H Stockholders Equity us-gaap/2024 Balance 0
0001641172-25-002362 7 10 EQ 0 H Shares Outstanding us-gaap/2024 Balance, shares 0
0001641172-25-002362 7 11 EQ 0 H Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options us-gaap/2024 Stock-based compensation 0
0001641172-25-002362 7 12 EQ 0 H Stock Issued During Period Value New Issues us-gaap/2024 Issuance of ordinary shares in ATM offering net of issuance costs of $2 0
0001641172-25-002362 7 13 EQ 0 H Stock Issued During Period Shares New Issues us-gaap/2024 Issuance of ordinary shares in at-the-market ("ATM") offering, net of issuance costs, shares 0
0001641172-25-002362 7 14 EQ 0 H Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax us-gaap/2024 Unrealized gain from marketable debt securities 0
0001641172-25-002362 7 15 EQ 0 H Net Income Loss us-gaap/2024 Net loss 0
0001641172-25-002362 7 16 EQ 0 H Stock Issued During Period Value Ordinary Shares Prefunded Warrants And Warrants Net Of Issuance Costs 0001641172-25-002362 Issuance of ordinary shares, pre-funded warrants, and warrants net of issuance costs of $756 thousand 0
0001641172-25-002362 7 17 EQ 0 H Stock Issued During Period Shares Ordinary Shares Prefunded Warrants And Warrants Net Of Issuance Costs 0001641172-25-002362 Issuance of ordinary shares, pre-funded warrants, and warrants net of issuance costs, shares 0
0001641172-25-002362 7 18 EQ 0 H Exercise Of Prefunded Warrants 0001641172-25-002362 Exercise of Pre-funded warrants 0
0001641172-25-002362 7 19 EQ 0 H Exercise Of Prefunded Warrants Shares 0001641172-25-002362 Exercise of Pre-funded warrants, shares 0
0001641172-25-002362 7 20 EQ 0 H Stock Issued During Period Value Acquisitions us-gaap/2024 Issuance of ordinary shares in relation to SEPA 0
0001641172-25-002362 7 21 EQ 0 H Stock Issued During Period Shares Acquisitions us-gaap/2024 Issuance of ordinary shares in relation to SEPA, shares 0
0001641172-25-002362 7 22 EQ 0 H Stock Issued During Period Value Other us-gaap/2024 Issuance of SEPA Commitment Shares 0
0001641172-25-002362 7 23 EQ 0 H Stock Issued During Period Shares Other us-gaap/2024 Issuance of SEPA Commitment Shares, shares 0
0001641172-25-002362 7 24 EQ 0 H Stock Issued During Period Value Restricted Stock Award Gross us-gaap/2024 Exercise of RSUs 0
0001641172-25-002362 7 25 EQ 0 H Stock Issued During Period Shares Restricted Stock Award Gross us-gaap/2024 Exercise of RSUs, shares 0
0001641172-25-002362 7 26 EQ 0 H Stock Issued During Period Value Exercise Of Warrants 0001641172-25-002362 Exercise of Warrants 0
0001641172-25-002362 7 27 EQ 0 H Stock Issued During Period Shares Exercise Of Warrants 0001641172-25-002362 Exercise of Warrants, shares 0
0001641172-25-002362 7 28 EQ 0 H Stockholders Equity us-gaap/2024 Balance 0
0001641172-25-002362 7 29 EQ 0 H Shares Outstanding us-gaap/2024 Balance, shares 0
0001641172-25-002362 8 1 EQ 1 H Payments Of Stock Issuance Costs us-gaap/2024 Stock issuance cost 0
0001641172-25-002362 8 2 EQ 1 H Warrants Net Of Issuance Costs 0001641172-25-002362 Warrants net of issuance costs 0
0001641172-25-002362 9 2 CF 0 H Net Income Loss us-gaap/2024 Net loss for the year 0
0001641172-25-002362 9 4 CF 0 H Depreciation And Amortization us-gaap/2024 Depreciation 0
0001641172-25-002362 9 5 CF 0 H Amortization Of Debt Discount Premium us-gaap/2024 Amortization of discount (premium) on marketable debt securities 0
0001641172-25-002362 9 6 CF 0 H Gain Loss On Sale Of Investments us-gaap/2024 Gain on sale of marketable debt securities 1
0001641172-25-002362 9 7 CF 0 H Financial Expenses 0001641172-25-002362 Finance expenses related to SEPA 0
0001641172-25-002362 9 8 CF 0 H Proceeds Finance Lease Interest Expense Income 0001641172-25-002362 Finance expenses (income) 0
0001641172-25-002362 9 9 CF 0 H Decrease In Shortterm Deposits 0001641172-25-002362 Decrease in short-term deposits 1
0001641172-25-002362 9 10 CF 0 H Income Loss From Equity Method Investments us-gaap/2024 Interest income from loan to associate 1
0001641172-25-002362 9 11 CF 0 H Share Based Compensation us-gaap/2024 Stock-based compensation expense 0
0001641172-25-002362 9 12 CF 0 H Other Asset Impairment Charges us-gaap/2024 Impairment of Associate 0
0001641172-25-002362 9 13 CF 0 H Change In Fair Value Convertible Note 0001641172-25-002362 Change in fair value convertible note 1
0001641172-25-002362 9 15 CF 0 H Increase Decrease In Accounts And Other Receivables us-gaap/2024 Decrease (increase) in other receivables 1
0001641172-25-002362 9 16 CF 0 H Increase Decrease In Accounts Payable Trade us-gaap/2024 Decrease in trade payables 0
0001641172-25-002362 9 17 CF 0 H Increase Decrease In Other Accounts Payable us-gaap/2024 Increase (decrease) in other payables 0
0001641172-25-002362 9 18 CF 0 H Net Cash Provided By Used In Operating Activities us-gaap/2024 Net cash used in operating activities 0
0001641172-25-002362 9 20 CF 0 H Payments To Acquire Property Plant And Equipment us-gaap/2024 Purchase of property and equipment 1
0001641172-25-002362 9 21 CF 0 H Payments For Investment In Available For Sale Securities 0001641172-25-002362 Investment in available for sale securities, 1
0001641172-25-002362 9 22 CF 0 H Payments For Proceeds From Investment In Convertible Note 0001641172-25-002362 Investment in Convertible note 1
0001641172-25-002362 9 23 CF 0 H Payments To Acquire Businesses Gross us-gaap/2024 Loan to associate 1
0001641172-25-002362 9 24 CF 0 H Payments For Proceeds From Investment In Associate 0001641172-25-002362 Investment in Associate 1
0001641172-25-002362 9 25 CF 0 H Proceeds From Sale Of Available For Sale Securities Debt us-gaap/2024 Proceeds from sale of available for sale securities, 0
0001641172-25-002362 9 26 CF 0 H Payments For Proceeds From Other Deposits us-gaap/2024 Proceeds from (investment in) short-term deposits, net 1
0001641172-25-002362 9 27 CF 0 H Net Cash Provided By Used In Investing Activities us-gaap/2024 Net cash provided by (used in) investing activities 0
0001641172-25-002362 9 28 CF 0 H Proceeds From Issuance Initial Public Offering us-gaap/2024 Issuance of ordinary shares in at-the-market offering, net of issuance costs 0
0001641172-25-002362 9 29 CF 0 H Proceeds From Issuance Of Common Stock us-gaap/2024 Issuance of ordinary shares in relation to SEPA 0
0001641172-25-002362 9 30 CF 0 H Issuance Of Ordinary Shares Prefunded Warrants And Warrants Net Of Issuance Costs 0001641172-25-002362 Issuance of ordinary shares, pre-funded warrants, and warrants net of issuance costs 1
0001641172-25-002362 9 31 CF 0 H Net Cash Provided By Used In Financing Activities us-gaap/2024 Net cash provided by financing activities 0
0001641172-25-002362 9 32 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2024 Increase (decrease) in cash, cash equivalents and restricted cash 0
0001641172-25-002362 9 33 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations us-gaap/2024 Cash and cash equivalents and restricted cash at the beginning of the year 0
0001641172-25-002362 9 34 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations us-gaap/2024 Cash, cash equivalents and restricted cash at the end of the year 0
0001641172-25-002362 9 36 CF 0 H Interest Paid Net us-gaap/2024 Cash received from interest 0
0001641172-25-002362 9 38 CF 0 H Conversion Of Convertible Note Into Investment In Associate 0001641172-25-002362 Conversion of convertible note into investment in associate 0

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
report Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site.
line Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived.
stmt The financial statement location to which the value of the “report” field pertains.
inpth Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700.
rfile The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file.
tag The tag chosen by the filer for this line item.
version The taxonomy identifier if the tag is a standard tag, otherwise adsh.
plabel The text presented on the line item, also known as a “preferred” label.
negating Flag to indicate whether the plabel is negating.